Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

The Quinism Foundation Calls for a Reopening of the Somalia Commission of Inquiry
  • USA - English


News provided by

The Quinism Foundation

Mar 12, 2018, 03:00 ET

Share this article

Share toX

Share this article

Share toX

WHITE RIVER JUNCTION, Vt. (PRWEB) March 12, 2018 -- The Quinism Foundation has sent a letter to Canadian Prime Minister Justin Trudeau calling for a reopening of the Somalia Commission of Inquiry to investigate the role of mefloquine poisoning in the brutal killing of Somali captive Shidane Arone, which occurred twenty five years ago this week.

On March 16, 1993, Master Corporal Clayton Matchee participated in a brutal beating of Arone that quickly led to the captive's death. Following his arrest, Matchee was subsequently found hanging in his cell, having suffered brain damage that rendered him unfit to subsequently stand trial.

Evidence has since emerged that prior to the killing, Matchee had been experiencing a serious adverse reaction to the antimalarial drug mefloquine (then also known as Lariam).

"As has been previously reported, at the time of the beating, Matchee was heard by then-Trooper John Dowe describing seeing camel spiders on the body of Shidane Arone and in the bunker in which they were located. According to Dowe, there were no camel spiders anywhere in the bunker, suggesting Matchee was hallucinating their presence," said Dr. Nevin. [1] "Visual hallucinations are a prominent feature of mefloquine psychosis," Dr. Nevin explained, "which can be associated with acts of violence towards the self and others."

In the wake of what became known as the Somalia Affair, Matchee's unit, the Canadian Airborne Regiment, was disbanded in disgrace. The subsequent Somalia Commission of Inquiry was due to investigate the role of mefloquine but was abruptly terminated prior to this investigation. The Commission nonetheless concluded in its final report that, "If mefloquine did, in fact, cause or contribute to some of the misbehaviour that is the subject of this Inquiry, [Canadian Forces] personnel who were influenced by the drug might be partly or totally excused for their behaviour. However, for reasons described above, we are not able to reach a conclusion on this issue." [2]

"As we mark the 25th anniversary of the Somalia Affair, I still seek justice for my family and for the family of Shidane Arone," said Marj Matchee, a member of The Quinism Foundation Advisory Committee. "My husband was never able to present evidence at a trial that he was under the influence of mefloquine. Without a full investigation into the role of mefloquine, the circumstances surrounding the killing will never be fully known."

In addition to calling for a reopening of the Somalia Commission of Inquiry, in its letter the foundation also joined the Royal Canadian Legion in calling on the Canadian Government to support research on mefloquine poisoning among Canadian veterans. [3]

About The Quinism Foundation

The Quinism Foundation promotes and supports education and research on neuropsychiatric quinism, also known as chronic quinoline encephalopathy, a medical disorder caused by poisoning by quinoline drugs including mefloquine and tafenoquine.

Founded in January 2018, the Quinism Foundation is supported by private donations and is advised by an international committee chaired by Mr. Andrew Bryce, of Dublin, Ireland. The Foundation's board of directors includes retired U.S. Navy Commander William Manofsky and retired U.S. Army Lieutenant Colonel Gregory Alderete.

Executive director Dr. Nevin is a Canadian-born board-certified occupational and preventive medicine physician and former U.S. Army medical officer and epidemiologist. He is author of more than 30 scientific publications on malaria and the quinoline antimalarials, including "Implications of Changes to the Mefloquine Product Monograph," published in the journal The Canadian Journal of Hospital Pharmacy (see: http://dx.doi.org/10.4212/cjhp.v70i4.1687).

1. Bambury, Brent. The Canadian military is issuing a malaria drug that can produce anxiety, paranoia and psychotic behaviour. CBC News. Available at: http://www.cbc.ca/radio/day6/episode-315-military-vs-mefloquine-top-holiday-books-of-2016-harry-benson-standing-rock-tees-and-more-1.3885384/the-canadian-military-is-issuing-a-malaria-drug-that-can-produce-anxiety-paranoia-and-psychotic-behaviour-1.3885389

2. Commission of Inquiry into the Deployment of Canadian Forces to Somalia. Dishonoured Legacy: The Lessons of the Somalia Affair. Executive Summary. Chapter ES-39, The Mefloquine Issue. 1997. Available at: http://publications.gc.ca/collections/collection_2015/bcp-pco/CP32-66-1997-eng.pdf

3. Royal Canadian Legion. Letter to the Ministers of National Defence and Veterans Affairs. November 3, 2016. Available at: http://www.legion.ca/docs/default-source/default-document-library/65-6-harjit-sajjan-and-kent-hehr-re-anti-malaria-medication-mefloquine.pdf

Remington Nevin, The Quinism Foundation, http://quinism.org, +1 (802) 291-3651, [email protected]

Modal title

The Quinism Foundation
The Quinism Foundation
The Quinism Foundation

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.